Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance

Reuters2026/08/26 14:27

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Ligand guided to 2026 adjusted EPS of $9-$9.5 on total revenue of $270-$310 million.
Royalty revenue outlook set at $225-$250 million; non-royalty revenue includes Captisol at $35-$40 million.
Q2 2026 revenue reached $64 million; royalties totaled $48 million; adjusted EPS came in at $2.37.
XOMA acquisition closed July 14, 2026; management expects immediate EPS accretion of about $0.5 in 2026, $1.5 in 2027.
$700 million 2031 convertible financing priced at 0% coupon with a 27.5% conversion premium; call spread targets no dilution up to $524.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief on August 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Ligand targets $150-$250 million in annual investments as royalty revenue tops $225 million in 2026 guidance

You may also like

Crypto prices